RNA interference screening identifies lenalidomide sensitizers in multiple myeloma, including RSK2

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Multiple myeloma (MM) treatment often involves lenalidomide, but resistance can develop.
• Identifying molecular targets to overcome lenalidomide resistance is crucial for improving patient outcomes.

Purpose of the Study:

• To identify novel molecular targets that modulate sensitivity to lenalidomide in multiple myeloma.
• To investigate the role of ribosomal protein S6 kinase (RSK2) as a potential sensitizer to lenalidomide therapy.

Main Methods:

• Utilized small interfering RNA (siRNA) screening in multiple myeloma cells to identify genes enhancing lenalidomide activity upon silencing.
• Assessed cytotoxicity and drug sensitivity in MM cell lines following gene knockdown or treatment with small molecule inhibitors.
• Analyzed downstream signaling pathways, including interferon regulatory factor 4 (IRF4) and MYC, affected by RSK2 inhibition.

Main Results:

• Identified 63 genes that enhance lenalidomide activity when silenced, with RSK2 being the most potent sensitizer.
• RSK2 knockdown and inhibition demonstrated significant synergy with lenalidomide, inducing cytotoxicity and increasing drug sensitivity in MM cells.
• RSK2 inhibition downregulated IRF4 and MYC, explaining the synergistic effect with lenalidomide and also sensitized cells to other MM drugs.

Conclusions:

• Inhibition of RSK2 represents a promising therapeutic strategy to enhance lenalidomide efficacy in multiple myeloma.
• Targeting RSK2 may offer a broadly applicable approach to overcome drug resistance and improve treatment outcomes in MM.
• Further research into RSK2 inhibition as an adjunct therapy for multiple myeloma is warranted.